Pfizer has also benefited from stable demand for established drugs. Photograph: Angela Weiss/AFP via Getty Images
Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations.
The drugmaker, which stuck to its full-year revenue forecast for the year, has benefited from chief executive Albert Bourla’s cost-cutting initiatives, new product launches and stable demand for establ
Continue Reading on The Irish Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.